Allergan Announces Dismissal of Antitrust Lawsuit against The Company.

Business Editors/Health/Medical Writers

IRVINE, Calif.--(BUSINESS WIRE)--Jan. 12, 2004

Allergan, Inc. (NYSE:AGN) announced today that Apotex, Inc., Apotex Corp., and Novex Pharma Inc. (the "Apotex Defendants") dismissed their antitrust lawsuit against Allergan and Roche Palo Alto, LLC. The lawsuit, which was pending in the United States District Court for the Northern District of California, was based on allegations concerning a patent infringement action brought by Allergan and Syntex LLC against the Apotex Defendants. Last week, the court held in favor of Allergan and Roche in the patent infringement action, finding that the patent at issue was valid, enforceable and infringed by the Apotex Defendants' proposed generic drug. The patent at issue covers Allergan's non-steroidal anti-inflammatory drug (NSAID) ACULAR(R) (ketorolac tromethamine ophthalmic solution 0.5%).

ACULAR(R) is the number one prescribed ophthalmic NSAID in both the United States and the rest of the world. ACULAR(R) is used for a range of conditions, including ocular allergy, photophobia, post-surgical ocular pain, and post-surgical ocular inflammation.

About Allergan, Inc.

Allergan, Inc., with headquarters in Irvine, California, is a technology-driven, global health care company providing eye care and specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care, neuromodulator, skin care and other specialty markets that deliver value to our customers, satisfy unmet medical needs, and improve patients' lives.